USG Operation COVID-19 Therapeutics Research Team-FDA Evaluations of the Neutralization Potency of Therapeutic Antibodies against SARS-CoV-2 Variants

National Institute Of Allergy And Infectious Diseases

Investigators

Abstract

The goal of this IAA is to identify mutations in SARS CoV-2 variants that confer resistance to therapeutic antibodies, and other mutations in the variants that can modify these effects.